SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?

V Quagliariello; A Bonelli; A Caronna; M C Lombari; G Conforti; M Libutti; R V Iaffaioli; M Berretta; G Botti; N Maurea

doi:10.26355/eurrev_202009_22867

SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?

V Quagliariello, A Bonelli, A Caronna, M C Lombari, G Conforti, M Libutti, R V Iaffaioli, M Berretta, G Botti, N Maurea

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Abstract

NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.

Original language	English
Pages (from-to)	9169-9171
Number of pages	3
Journal	European Review for Medical and Pharmacological Sciences
Volume	24
Issue number	17
DOIs	https://doi.org/10.26355/eurrev_202009_22867
Publication status	Published - Sep 2020

Keywords

Betacoronavirus/isolation & purification
Cardiovascular Diseases/prevention & control
Clinical Trials as Topic
Coronavirus Infections/diagnosis
Cytokines/metabolism
Humans
Inflammasomes/metabolism
Myocarditis/prevention & control
NLR Family, Pyrin Domain-Containing 3 Protein/antagonists & inhibitors
Nitriles/therapeutic use
Pandemics
Pneumonia, Viral/diagnosis
Prognosis
Venous Thromboembolism/prevention & control
ortho-Aminobenzoates/therapeutic use

Access to Document

10.26355/eurrev_202009_22867

Cite this

Quagliariello, V., Bonelli, A., Caronna, A., Lombari, M. C., Conforti, G., Libutti, M., Iaffaioli, R. V., Berretta, M., Botti, G., & Maurea, N. (2020). SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? European Review for Medical and Pharmacological Sciences, 24(17), 9169-9171. https://doi.org/10.26355/eurrev_202009_22867

SARS-CoV-2 infection : NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? / Quagliariello, V ; Bonelli, A ; Caronna, A ; Lombari, M C ; Conforti, G; Libutti, M; Iaffaioli, R V; Berretta, M; Botti, G; Maurea, N.

In: European Review for Medical and Pharmacological Sciences, Vol. 24, No. 17, 09.2020, p. 9169-9171.

Research output: Contribution to journal › Article › peer-review

Quagliariello, V , Bonelli, A , Caronna, A , Lombari, MC , Conforti, G, Libutti, M, Iaffaioli, RV, Berretta, M, Botti, G & Maurea, N 2020, 'SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?', European Review for Medical and Pharmacological Sciences, vol. 24, no. 17, pp. 9169-9171. https://doi.org/10.26355/eurrev_202009_22867

@article{3d83f59c70b5473e9667dc7dc21931a2,

title = "SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?",

abstract = "NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.",

keywords = "Betacoronavirus/isolation & purification, Cardiovascular Diseases/prevention & control, Clinical Trials as Topic, Coronavirus Infections/diagnosis, Cytokines/metabolism, Humans, Inflammasomes/metabolism, Myocarditis/prevention & control, NLR Family, Pyrin Domain-Containing 3 Protein/antagonists & inhibitors, Nitriles/therapeutic use, Pandemics, Pneumonia, Viral/diagnosis, Prognosis, Venous Thromboembolism/prevention & control, ortho-Aminobenzoates/therapeutic use",

author = "V Quagliariello and A Bonelli and A Caronna and Lombari, {M C} and G Conforti and M Libutti and Iaffaioli, {R V} and M Berretta and G Botti and N Maurea",

year = "2020",

month = sep,

doi = "10.26355/eurrev_202009_22867",

language = "English",

volume = "24",

pages = "9169--9171",

journal = "European Review for Medical and Pharmacological Sciences",

issn = "1128-3602",

publisher = "Verduci Editore",

number = "17",

}

TY - JOUR

T1 - SARS-CoV-2 infection

T2 - NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?

AU - Quagliariello, V

AU - Bonelli, A

AU - Caronna, A

AU - Lombari, M C

AU - Conforti, G

AU - Libutti, M

AU - Iaffaioli, R V

AU - Berretta, M

AU - Botti, G

AU - Maurea, N

PY - 2020/9

Y1 - 2020/9

N2 - NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.

AB - NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.

KW - Betacoronavirus/isolation & purification

KW - Cardiovascular Diseases/prevention & control

KW - Clinical Trials as Topic

KW - Coronavirus Infections/diagnosis

KW - Cytokines/metabolism

KW - Humans

KW - Inflammasomes/metabolism

KW - Myocarditis/prevention & control

KW - NLR Family, Pyrin Domain-Containing 3 Protein/antagonists & inhibitors

KW - Nitriles/therapeutic use

KW - Pandemics

KW - Pneumonia, Viral/diagnosis

KW - Prognosis

KW - Venous Thromboembolism/prevention & control

KW - ortho-Aminobenzoates/therapeutic use

U2 - 10.26355/eurrev_202009_22867

DO - 10.26355/eurrev_202009_22867

M3 - Article

C2 - 32965010

VL - 24

SP - 9169

EP - 9171

JO - European Review for Medical and Pharmacological Sciences

JF - European Review for Medical and Pharmacological Sciences

SN - 1128-3602

IS - 17

ER -

SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?

Abstract

Keywords

Access to Document

Fingerprint

Cite this